Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma

被引：10
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, 377-2 Ohno Higashi, Osaka 5898511, Japan
来源：
LIVER CANCER | 2018年 / 7卷 / 04期
关键词：
REACH;
D O I：
10.1159/000492534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：305 / 311
页数：7
相关论文
共 5 条
[1]   Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study [J].
Chau, Ian ;
Park, Joon Oh ;
Ryoo, Baek-Yeol ;
Yen, Chia-Jui ;
Poon, Ronnie ;
Pastorelli, Davide ;
Blanc, Jean-Frederic ;
Kudo, Masatoshi ;
Pfiffer, Tulio ;
Hatano, Etsuro ;
Chung, Hyun Cheol ;
Kopeckova, Katerina ;
Phelip, Jean-Marc ;
Brandi, Giovanni ;
Ohkawa, Shinichi ;
Li, Chung-Pin ;
Okusaka, Takuji ;
Hsu, Yanzhi ;
Abada, Paolo B. ;
Zhu, Andrew X. .
BRITISH JOURNAL OF CANCER, 2018, 119 (01) :19-26
[2]   Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial [J].
Kudo, Masatoshi ;
Hatano, Etsuro ;
Ohkawa, Shinichi ;
Fujii, Hirofumi ;
Masumoto, Akihide ;
Furuse, Junji ;
Wada, Yoshiyuki ;
Ishii, Hiroshi ;
Obi, Shuntaro ;
Kaneko, Shuichi ;
Kawazoe, Seiji ;
Yokosuka, Osamu ;
Ikeda, Masafumi ;
Ukai, Katsuaki ;
Morita, Sojiro ;
Tsuji, Akihito ;
Kudo, Toshihiro ;
Shimada, Mitsuo ;
Osaki, Yukio ;
Tateishi, Ryosuke ;
Sugiyama, Gen ;
Abada, Paolo Benjamin ;
Yang, Ling ;
Okusaka, Takuji ;
Zhu, Andrew Xiuxuan .
JOURNAL OF GASTROENTEROLOGY, 2017, 52 (04) :494-503
[3]   Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis [J].
Park, Joon Oh ;
Ryoo, Baek-Yeol ;
Yen, Chia-Jui ;
Kudo, Masatoshi ;
Yang, Ling ;
Abada, Paolo B. ;
Cheng, Rebecca ;
Orlando, Mauro ;
Zhu, Andrew X. ;
Okusaka, Takuji .
ONCOTARGET, 2016, 7 (46) :75482-75491
[4]   Whole exome sequencing (WES) to define the genomic landscape of young lung cancer patients (pts). [J].
Wu, Xiaoliang ;
Chen, Yanwen ;
Zhu, Lin ;
Stylianou, Eleni ;
Barnholtz-Sloan, Jill ;
Zhang, Zhenfeng ;
Ma, Patrick C. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5]   Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial [J].
Zhu, Andrew X. ;
Park, Joon Oh ;
Ryoo, Baek-Yeol ;
Yen, Chia-Jui ;
Poon, Ronnie ;
Pastorelli, Davide ;
Blanc, Jean-Frederic ;
Chung, Hyun Cheol ;
Baron, Ari D. ;
Pfiffer, Tulio Eduardo Flesch ;
Okusaka, Takuji ;
Kubackova, Katerina ;
Trojan, Jorg ;
Sastre, Javier ;
Chau, Ian ;
Chang, Shao-Chun ;
Abada, Paolo B. ;
Yang, Ling ;
Schwartz, Jonathan D. ;
Kudo, Masatoshi .
LANCET ONCOLOGY, 2015, 16 (07) :859-870
1